Molinalogo

Measure

2021

2022

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

71.79%

74.20%

64.52%

Annual Dental Visits (ADV)

NB

NB

53.67%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

42.12%

42.80%

46.09%

Appropriate Testing for Pharyngitis (CWP)

44.96%

33.72%

74.02%

Appropriate Treatment for Upper Respiratory Infection (URI)

90.58%

92.01%

92.46%

Asthma Medication Ratio (AMR) Total

60.39%

59.49%

68.21%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

50.02%

44.30%

58.74%

Breast Cancer Screening (BCS)

55.83%

51.27%

53.96%

Cervical Cancer Screening (CCS)

57.18%

57.66%

60.83%

Childhood Immunization Status (CIS) Combination #10

40.15%

34.55%

39.42%

Chlamydia Screening in Women (CHL) Total

61.24%

62.98%

60.24%

Comprehensive Diabetes Care (CDC) BP Control < 140/90

54.26%

59.12%

65.21%

Comprehensive Diabetes Care (CDC) HbA1c Control <8.0%

50.12%

51.09%

52.80%

Comprehensive Diabetes Care (CDC) Eye Exam

59.85%

52.55%

54.74%

Controlling High Blood Pressure (CBP)

54.99%

54.99%

63.50%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

76.33%

82.92%

81.21%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

3.84%

3.47%

16.16%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

11.10%

7.84%

45.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

NB

NB

42.75%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

6.36%

8.3%

37.86%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

39.05%

41.41%

55.40%

Immunizations for Adolescents (IMA) Combination #2

39.42%

33.33%

39.16%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

NB

6.77%

16.57%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

NA

0.00%

39.29%

Pharmacotherapy for Opioid Use Disorder (POD) Total

10.81%

19.23%

33.15%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

65.38%

64.66%

74.76%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

82.82%

86.89%

87.83%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

90.64%

93.61%

≤ 94.44%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

89.29%

85.40%

87.83%

Prenatal and Postpartum Care (PPC) Postpartum Care

78.10%

78.35%

80.00%

Prenatal Immunization Status (PRS) Combination Rate

NR

24.15%

27.32%

Risk of Continued Opioid Use (COU) 31-Day Total

3.54%

2.73%

≤ 2.35%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

80.20%

79.40%

82.29%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

75.95%

74.47%

73.75%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

71.02%

71.78%

68.32%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

69.67%

68.31%

70.00%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

NA

NA

65.63%

Use of Imaging Studies for Low Back Pain (LBP)

74.70%

74.83%

76.82%

Use of Opioids at High Dosage (HDO)

3.17%

5.27%

≤ 2.65%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

1.81%

1.47%

≤ 0.90%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

86.86%

84.91%

82.73%